Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
Year: 2024
Type: article
Study design: Observational Study
Authors: Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H. Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E. Drolen, Tatyana Feldman, Tarek Haykal, Caroline A. Nebhan, Swetha Kambhampati Thiruvengadam, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B. Johnson, Ankit Mangla, Christopher Dittus, Praful Ravi, Robert A. Baiocchi, Elizabeth Y. Chiao, Paul G. Rubinstein, Sarvari V. Yellapragada, Ann S. LaCasce, Guru P. Sonpavde, Abdul Rafeh Naqash, Alex F. Herrera
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Yale University, Brigham and Women's Hospital, The University of Texas MD Anderson Cancer Center, Washington Hospital, MedStar Georgetown University Hospital, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Hackensack University Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Duke Medical Center, The Ohio State University, Vanderbilt University Medical Center, City Of Hope National Medical Center, University of North Carolina at Chapel Hill, University Hospitals Seidman Cancer Center, Dana-Farber Cancer Institute, John H. Stroger, Jr. Hospital of Cook County, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Conquer Cancer Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, Regeneron Pharmaceuticals, Taiho Pharmaceutical, Exelixis, Jazz Pharmaceuticals, Jounce Therapeutics, Mirati Therapeutics, BeiGene, Incyte, Alimera Sciences, Moderna, UroGen Pharma, Seagen, Springworks Therapeutics, Eisai, Astellas Pharma, Servier, MorphoSys, Ipsen, National Institutes of Health, Genentech, Takeda Oncology, Kite Pharma, Pharmacyclics, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences, Daiichi Sankyo Europe
OpenAlex ID: W4393999951